Newborn screening for inherited disorders has been heralded as one of the 10 greatest public health achievements of the first decade of the 21st century.1 The ability to pre-symptomatically identify newborn babies at risk of… Read more >
Don Mason reviews the state of newborn screening (NBS) programs around the world.
Reflecting on a common concern in newborn screening: Reliability.
Waters’ legacy of purposeful innovation continues with the recently introduced RenataDX Screening System, a flow-injection tandem mass spectrometry system for high-throughput analysis of extracted dried blood spots and other physiological matrices.
Newborn screening for inherited metabolic disorders dates to the early 1960s when Dr. Robert Guthrie in Buffalo, New York developed the first screening test for phenylketonuria (or PKU), a metabolic disease in which patients can’t metabolize the amino acid phenylalanine.
Mass spectrometry has been game changer in newborn screening because rather than having a single test for a single condition, there was now a technique that provided a single test for a large number of different conditions.
Labs like King’s Liver Laboratories in London need to analyze thousands of samples with fast turnaround times, so it’s critical to have reliable LC-MS/MS instrumentation that works every day and provides accurate and precise results.
Let’s look at the area of organ transplantation as an example of how the TDM field is developing. We look at the progression from immunoassays to LC-MS assays.
Therapeutic drug monitoring (TDM) is a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug concentration levels in blood. It enables adjustment of drug dosage for individuals to improve patient outcomes.
“Fast is fine; but accuracy is everything.” The quote is attributed to the famous Wyatt Earp, a sharpshooter and lawman who, with help from his two brothers, sent three outlaws to their graves in the… Read more >